Mounjaro vs Ozempic: Which Weight Loss Drug is Better? 2026 Guide

Mounjaro and Ozempic are not two strengths of one drug. Mounjaro is tirzepatide. Ozempic is semaglutide. They are prescribed for overlapping reasons, and a headline that declares a winner is not a prescription.

What each drug acts on

Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and on GIP. Both slow the stomach, reduce appetite, and, in people with type 2 diabetes, lower blood sugar. The second receptor is the pharmacological difference. It is not, by itself, a reason to start tirzepatide in someone who has not been evaluated.

Brand names and what they were approved for

The brand follows the indication.

• Ozempic is semaglutide approved for type 2 diabetes. Wegovy is semaglutide approved for chronic weight management.
• Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is tirzepatide approved for chronic weight management.

Asking for "Mounjaro for weight" or "Ozempic for weight" may lead the clinician to the weight-management brand of the same ingredient, to the diabetes brand when diabetes is the diagnosis, or to neither. Insurance often follows the same split. A plan that pays for a diabetes brand may not pay for a weight-management brand, and the reverse is also true.

How they are taken

Both are once-weekly injections under the skin. Both start at a low dose and increase on a schedule if the drug is tolerated. The milligrams are not interchangeable. A milligram of tirzepatide is not a milligram of semaglutide, and patients who switch are restarted on the new drug's schedule rather than converted with a homemade ratio.

The practical differences that patients feel are the pen, the dose steps, the side effects they personally get, and the price at their pharmacy. Those are visible only after a prescription is written for a named product.

Side effects

Nausea, vomiting, diarrhea, constipation, and early fullness happen with both. They are most noticeable while the dose is increasing. A history of pancreatitis, severe stomach disease, or a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 is a reason to avoid the class, not a tie-breaker between the two brands. Gallbladder symptoms and dehydration from vomiting are reasons to call the prescriber.

People sometimes tolerate one drug after stopping the other. That is a clinical observation at the next visit. It is not something to test by taking leftover pens.

Why a trial percentage is not the decision

Each approved product was studied in its own program, in its own patients, at its own top dose. Those programs are not a single head-to-head race that a website can turn into "this one wins by this many percent." Quoting a body-weight percentage from one program next to a percentage from another program, as if every reader will lose that amount, overstates what the studies found. The clinician's comparison is narrower: the diagnosis on this chart, the dose the person can tolerate, the plan that will actually cover a product, and the side effects that have already happened.

A longer account of the two ingredients is in semaglutide and tirzepatide. The visit that starts either drug is described in how an Ozempic prescription works and on the GLP-1 treatment page.

What this article does not do

This page explains the decision. It does not approve a medication, set a dose, or replace a clinician who can see the rest of the history. Seek in-person or emergency care for severe or rapidly worsening symptoms.

Who this is for in Maryland

The patients this page is for live in Baltimore, the Washington suburbs, and the Eastern Shore.

This article is for those patients when they are deciding whether Mounjaro or Ozempic fits a visit with MarylandDoc.

How the MarylandDoc visit applies

The MarylandDoc visit for this topic starts with a structured intake covering symptoms, medications, allergies, and prior treatment response. A Maryland-licensed physician (MD) reviews whether Mounjaro or Ozempic is appropriate, whether labs are required, and whether another approach is safer. If a prescription is indicated, it is sent to a pharmacy the patient can use in Maryland. That prescription is not a referral to a District of Columbia or Northern Virginia clinic.

Local access

A patient in Baltimore, the Washington suburbs, and the Eastern Shore should compare Mounjaro or Ozempic with care already available through Johns Hopkins Medicine or the University of Maryland Medical System, not with a District of Columbia or Northern Virginia clinic. Labs, when needed, can be drawn through a local partner in Maryland.